Life sciences and health tech news roundup: AIlen Institute’s new CEO, AI2’s incubator, and more
The legacy of the late Microsoft co-founder Paul Allen lives on at some of Seattle’s most progressive institutions.
This 7 days GeekWire profiled the AI2 incubator, a department of the Allen Institute for AI (AI2) introduced by Allen in 2013. GeekWire co-founder Todd Bishop explored the earlier and the long term of the incubator, which is significantly fostering wellbeing tech and biotech corporations including BirchAI and Modulus Therapeutics.
We also interviewed the new CEO of the Allen Institute, the life sciences counterpart to the AI2. Rui Costa spoke about team investigation, his commitment to variety, and his look at on the institute’s method to new marketplace partnerships.
Examine on for this and additional daily life sciences and wellness tech protection in the Pacific Northwest from GeekWire and further than, together with a examine showcasing the Allen Institute’s new visualization software, the “Simularium Viewer.”
— Inside of the AI2 Incubator: Microsoft co-founder’s unfinished legacy fuels quest for new AI startups
— The neural dynamics of teamwork: New Allen Institute CEO on variety and impression in lifetime science
— Seattle startup raises $9.7M for scientific trial to exam inhaled CBD as nervousness remedy
New scientific tests:
- The Allen Institute’s “Simularium Viewer” enables computational visualization of biological processes and was explained in a review this week. Scientists showcased video simulations of a nanoparticle wrapped by an outer coat, a lung infected by the COVID-19 virus, and the bacterium E. Coli dividing.
- Alpine Immune Sciences printed a preclinical analyze on its lead immuno-oncology prospect, an immune “checkpoint inhibitor” directed towards three targets at the moment. The Seattle biotech business is screening the compound in two scientific trials.
- Scientists at Fred Hutch and their colleagues identified that breast cancer procedure may possibly final result in an elevated hazard for cardiovascular occasions. “Scientists and clinicians need to prioritize investigation that will minimize this chance,” claimed Fred Hutch investigator Heather Greenlee in a news release.
- A noninvasive ultrasound approach examined by University of Washington surgeon Jonathan Harper and his colleagues can dissipate kidney stones. The technique may well guide to less invasive procedure strategies and is accredited to Silicon Valley company SonoMotion.
Boosting cash:
- The College of Washington will make a new tuberculosis investigation middle with up to $5.3 million from the U.S. Countrywide Institutes of Overall health, declared this week.
- AVM Biotechnology landed a $1.6 million little enterprise grant from the Countrywide Institutes of Health. The grant will guidance preclinical exploration on the Seattle company’s lead compound, based mostly on the corticosteroid dexamethasone. The compound triggers a unique kind of T mobile and will be tested in sort 1 diabetic issues in mouse models. Meanwhile, the firm is enrolling clients in a phase 1/2 scientific demo testing the compound in blood cancers.
Fostering startups:
- The College of Washington Startup Occupation & Internship Reasonable this year was dwell and in man or woman. Biotech firms ended up front and centre.
- Uncover Ventures and the Washington Point out Section of Commerce picked 10 tech startups and founders for its to start with “Equitable Innovations Accelerator.” Health tech firms Coltrain, Litesprite and GoldenSHERPA produced the slash.
Moving up and overseas:
- Fred Hutch investigator Phil Greenberg was elected president of the American Association for Cancer Study.
- Seattle biotech enterprise Nanostring is increasing, opening a European headquarters in Amsterdam.
- Adaptive Biotechnologies’ previous main health care officer Lance Baldo has a new task with the exact title at South San Francisco-primarily based Freenome.
- Inventprise has a new CEO, Yves Leurquin, and two new board associates. The Redmond, Clean.-dependent organization also acquired $30 million of up to $90 million pledged by the Invoice & Melinda Gates Basis to guidance clinical enhancement of the company’s vaccine for pediatric pneumococcal disease.